Our Advanced Alectinib Program Work Even When You Go To Bed!

88(95% CI: 0.85�C0.90), which indicated a median level of overall diagnostic value of sTREM-1 for LRTI. The pretest probability of LRTI in our study was 44%. The Fagan's nomogram indicated that the sTREM-1 detection would raise the post-test probability to 74% and decrease the post-test probability to 14% (Fig. S1 available in the Supporting Information). The chi-square test could be used to examine whether the statistically significant heterogeneity existed among included the studies. The I2 for the pooled sensitivity, specificity, PLR, NLR and DOR was 75.2%, 88.6%, 90.26%, 75.39% and 100%, which showed substantial heterogeneity among studies. Therefore, univariate meta-regression analysis was performed to find the sources of Sitaxentan potential heterogeneity among included trails. We included the following variables: prevalence of LRTI (��50% vs Anti-cancer Compound Library ELISA), sample source (serum vs BALF), cut-off value (��200?pg/mL vs Alectinib purchase under SROC curve was 0.90 (95% CI: 0.87�C0.92), which showed a median capacity of overall test accuracy. Thus, above results demonstrated that the overall diagnostic value of sTREM-1 was similar for LRTI, community-acquired LRTI and hospital-acquired LRTI. We also analysed the value of sTREM-1 for distinguishing culture-positive LRTI from culture-negative diseases. The pooled sensitivity and specificity was 0.79 (95% CI: 0.53�C0.92) and 0.80 (95% CI: 0.53�C0.93). The PLR, NLR and DOR were 3.9 (95% CI: 1.4�C11.0), 0.26 (95% CI: 0.10�C0.69) and 15 (95% CI: 3�C82).